News
Unique collaboration to build Nordic health industry
A new collaboration agreement between AstraZeneca, Oslo Cancer Cluster, and Oslo Science City aims to strengthen the Nordic health industry.
A peak into Cancer Crosslinks
World-leading translational cancer research entered Oslo Cancer Cluster Innovation Park last week and created a buzz.
Making Cancer Crosslinks possible
Meet the sponsors behind Cancer Crosslinks 2024: Bristol Myers Squibb and Daiichi-Sankyo.
Meet our new members
Meet the members who recently joined or re-joined our cluster.
Cancer Crosslinks 2024: meet the speakers
Join us for a day of educational talks and mingling with colleagues in the oncology community.
Data power and moonshots
The Cancer Mission Hub Norway arranged its yearly high-level meeting for the fourth time. This is what was discussed.
Member companies secure NOK 92 Million
Oslo Cancer Cluster Members secure a staggering NOK 92 Million from the Research Council of Norway. The Research Council of Norway allocates NOK 494 million to 39 research-based innovation projects in companies across the entire country, marking a significant boost for cancer innovation. Oslo Cancer Cluster celebrates the success of several member companies, who collectively […]
Highlights from Oslo Cancer Cluster in 2023
Here are seven highlights from this eventful year.
Our new communications advisor
Meet Margit Selsjord, Oslo Cancer Cluster's new communications advisor.
Nordic Life Science Days 2023
This year’s Nordic Life Science Days took place in Copenhagen on 29-30 November. Since 2015, Oslo Cancer Cluster has coordinated the joint booth Norway for Life Science, promoting the Norwegian healthcare and life science industry. This year together with Norway Health Tech, The Life Science Cluster, Norwegian Smart Care Cluster, Centre for Digital Life Norway, […]
Six-month milestone
The foundations of the ECHoS project are laid and Cancer Mission activities are speeding up in Norway.
Personalising breast cancer screening in Norway
Are polygenic risk scores the answer?